Emergent BioSolutions news from FierceVaccines
NewsVaxGen sells anthrax vaccine to its old rival
Reduced to a skeleton crew and a bleak outlook, South San Francisco-based VaxGen sold its experimental anthrax vaccine to its former chief rival, Emergent BioSolutions, for $2 million down and up to Read more...
| Press ReleasesPRESS RELEASE: HHS Remains Committed to Procurement of BioThrax Under Current Contract U.S. Department of Health and Human Services Remains Committed to Procurement of BioThrax Under Current Contract ROCKVILLE, Md. -- Nov. 19, 2007--Emergent BioSolutions Inc. (NYSE:EBS) announced Read more... PRESS RELEASE: Emergent BioSolutions Signs $448 Million Three Year Contract with Department of Health and Human Services Emergent BioSolutions Signs $448 Million Three Year Contract with Department of Health and Human Services Emergent BioSolutions, announced today that it has signed a three year contract with the Read more... |
Get more Emergent BioSolutions coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight